Skip to content
Trial Eligibility
Menu

Lung Cancer Clinical Trials Recruiting in the US

793 studies for Lung Cancer are recruiting at 12,784 US sites, according to ClinicalTrials.gov data processed .

Lung cancer is a disease in which cells in the lungs grow out of control.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Top Lung Cancer studies by number of US sites

Showing 30 studies, most US recruiting sites first.
  1. Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

    NCT03851445

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    946 US recruiting sites
  2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    NCT04267848

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    619 US recruiting sites
  3. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    NCT05334069

    • Observational
    • Ages 40 to 75 years
    • Sex: All
    • Accepts healthy volunteers
    Recruiting sites
    610 US recruiting sites
  4. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    NCT06418204

    • Observational
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    482 US recruiting sites
  5. Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

    NCT05624996

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    444 US recruiting sites
  6. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    NCT06616584

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    397 US recruiting sites
  7. Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

    NCT05642572

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    370 US recruiting sites
  8. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    NCT04181060

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    322 US recruiting sites
  9. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    NCT06498635

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    275 US recruiting sites
  10. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    NCT06096844

    • Phase 3
    • Ages 70 years and older
    • Sex: All
    Recruiting sites
    264 US recruiting sites
  11. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

    NCT06116682

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    249 US recruiting sites
  12. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    NCT06031688

    • Phase 2
    • Ages 18 Minutes and older
    • Sex: All
    Recruiting sites
    246 US recruiting sites
  13. A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

    NCT07144280

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    241 US recruiting sites
  14. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    NCT07222566

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    213 US recruiting sites
  15. Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

    NCT03191149

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    212 US recruiting sites
  16. LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

    NCT06073431

    • Observational
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    195 US recruiting sites
  17. Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

    NCT06769126

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    145 US recruiting sites
  18. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    NCT06667076

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    119 US recruiting sites
  19. A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

    NCT07293247

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    110 US recruiting sites
  20. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    NCT07388524

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    97 US recruiting sites
  21. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    NCT06767514

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    96 US recruiting sites
  22. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    NCT04389632

    • Phase 1
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    94 US recruiting sites
  23. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    NCT06119581

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    86 US recruiting sites
  24. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    NCT06758401

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    83 US recruiting sites
  25. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    NCT06890598

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    78 US recruiting sites
  26. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

    NCT04613596

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    74 US recruiting sites
  27. Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

    NCT06686771

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    71 US recruiting sites
  28. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All
    Recruiting sites
    67 US recruiting sites
  29. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    NCT06793215

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    63 US recruiting sites
  30. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

    NCT06627647

    • Phase 3
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    61 US recruiting sites

By city

Lung Cancer clinical trials by city

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Lung Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.